Market research
1HB1.F Heat Biologics, Inc
F EUR Healthcare
Latest close
As of 04 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 18M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.43
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 18M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.43
About
About Heat Biologics, Inc
Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. It is developing HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer. The company's preclinical stage products include HS-130 for the treatment of advanced solid tumors; PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25 signaling; and PTX-45, a human TL1A-Ig fusion protein that acts as an agonist of TNFRSF25 signaling. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.
Research context
Heat Biologics, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 1HB1.F discussion.
5 years, 6 months ago
Heat Biologics, Inc is currently in a long term downtrend where the price is trading 87.9% below its 200 day moving average.
From a valuation standpoint, the stock is 98.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 15.5.
Heat Biologics, Inc's total revenue rose by 13096.6% to $850K since the same quarter in the previous year.
Its net income has dropped by 42.9% to $-9M since the same quarter in the previous year.
Finally, its free cash flow fell by 26.3% to $-6M since the same quarter in the previous year.
Based on the above factors, Heat Biologics, Inc gets an overall score of 2/5.